RecruitingPhase 2NCT06654440

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

An Open-label, Multicenter Phase II Clinical Study of SHR-A2102 for Injection in the Treatment of Advanced Gynaecological Malignancies

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment

100 participants

Start Date

Nov 15, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Gynecological Malignancy

Summary

The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-A2102 for injection for people with advanced gynecological malignancy. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-A2102 for injection

SHR-A2102 for injection

Locations(1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06654440